You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 120 No. 11, November 1994 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Articles
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Growth Inhibition by Interferon Beta and Gamma of MDA 886Ln Monolayer Cells and Multicellular Tumor Spheroids

A Differentiation Therapy Model for Squamous Cell Carcinoma

Peter G. Sacks, PhD; Tomas Racz, MD; Stimson P. Schantz, MD; Michael G. Rosenblum, PhD

Arch Otolaryngol Head Neck Surg. 1994;120(11):1267-1272.


Abstract

Objective
The ability of interferon beta (IFN-β) and interferon gamma (IFN-{gamma}) to modulate growth and differentiation of squamous carcinoma was studied.

Design
Two squamous carcinoma models (MDA 886Ln monolayer cells and multicellular tumor spheroids [MTSs], an in vitro system with three-dimensional in vivo—like structure) were used. Effects of interferons were examined with growth and differentiation assays.

Results
In 5-day monolayer growth assays, both interferons (IFNs) exhibited dose-dependent growth inhibition between 0 and 104 U/mL; IFN-{gamma} was more inhibitory than IFN-β (inhibitory concentration for 50% inhibition of 9 and 900 U/mL for IFN-{gamma} and IFN-β, respectively). Multicellular tumor spheroid growth was examined by sizing MTSs over a 9-day growth period. Multicellular tumor spheroids were resistant to IFN-β with exposures of up to 50 000 U/mL. Similarly, MTSs were resistant to IFN-{gamma} for the first several days, with growth inhibition becoming evident between days 7 to 9 of culture. As a marker of differentiation, transglutaminase activity was quantified after 5 days of treatment. Both IFNs induced increased transglutaminase activity in monolayer cells: IFN-β was twice as effective as IFN-{gamma}. In contrast, 5-day treated MTSs showed no induction although their endogenous activity was higher. Flow cytometric analysis of monolayer cells for induction of class I and II major histocompatibility complex showed that both IFNs induced class I antigens but only IFN-{gamma} could induce class II.

Conclusions
With their three-dimensional architecture, MTSs were more resistant to IFN-induced growth inhibition and differentiation induction than monolayer cells. Thus, mode of growth (monolayer vs MTS) is an important factor in responsiveness to IFN treatment; this suggests that MTSs may produce information that is more relevant to in vivo usage than monolayer cells.

(Arch Otolaryngol Head Neck Surg. 1994;120:1267-1272)



Author Affiliations

From the Memorial Sloan-Kettering Cancer Center, New York, NY (Drs Sacks and Schantz); R-Klinika Felsozoldmali, Budapest, Hungary (Dr Racz); and the University of Texas M. D. Anderson Cancer Center, Houston (Dr Rosenblum).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Interferon Gamma Enhances Lymphokine-Activated Killer Cell Adhesion but Not Lysis of Head and Neck Squamous Cell Carcinoma
Scher et al.
Arch Otolaryngol Head Neck Surg 1995;121:1271-1275.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1994 American Medical Association. All Rights Reserved.